Other languages Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Real-time Estimate Cboe BZX Other stock markets 10:53:42 2024-06-03 am EDT			5-day change	1st Jan Change
6.665 ^USD	+53.22%		+70.27%	+10.88%

Jun. 02	Transcript : Affimed N.V. - Special Call
May. 29	Affimed Says US FDA Grants Fast-Track Designation for Potential Lung Cancer Therapy	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Transcript : Affimed N.V. - Special Call	Jun. 01
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort	Jun. 01
Affimed Says US FDA Grants Fast-Track Designation for Potential Lung Cancer Therapy	May. 29
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer	May. 29
Affimed N.V. Receives Fast Track Designation for Combination Therapy of Afm24 with Atezolizumab for Egfr Wild-Type Non-Small Cell Lung Cancer	May. 29
Affimed Announces Annual General Meeting of Shareholders	May. 28
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024	May. 23
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024	May. 23
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress	May. 14
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology	Apr. 24
Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating	Apr. 01
HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating	Apr. 01
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Transcript : Affimed N.V., 2023 Earnings Call, Mar 28, 2024	Mar. 28
Affimed Reports 2023 Financial Results and Operational Progress	Mar. 28
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024	Mar. 21
Affimed N : Form 6-K	Mar. 11
Affimed Announces 1-for-10 Reverse Stock Split	Mar. 06
AFFIMED ANNOUNCES LEADERSHIP CHANGE AND ORGANIZATIONAL RESTRUCTURING	Jan. 09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Other languages

Filters